Clinical Results of Sodium Borocaptate (BSH)-Based Intraoperative Boron Neutron Capture Therapy (IO-BNCT)
The first clinical trials of BNCT were conducted at the Brookhaven Graphic Reactor and the Brookhaven Medical Research Reactor during 1951 and 1952 and at the Massachusetts Institute of Technology Reactor from 1959 to 1962 [3]. The boron compounds used we
- PDF / 411,781 Bytes
- 9 Pages / 439.37 x 666.14 pts Page_size
- 8 Downloads / 202 Views
21
Teruyoshi Kageji, Yoshinobu Nakagawa, and Hiroaki Kumada
Contents 21.1 Introduction .................................................................................................................
390
21.2 Actual State-of-the-Art Treatment ............................................................................ 390 21.3 Rationale for BNCT .................................................................................................... 391 21.4 Technical Aspect .......................................................................................................... 21.4.1 Dose Planning ................................................................................................. 21.4.2 Patients and Protocols ..................................................................................... 21.4.3 Procedure of BSH-Based Intraoperative BNCT (IO-BNCT) .........................
391 391 392 392
21.5 Results ......................................................................................................................... 392 21.5.1 Thermal Neutron and BSH-Based IO-BNCT (1977–1997) ........................... 392 21.5.2 Epithermal Neutron and BSH-Based IO-BNCT (1998–2004) ...................... 393 21.6 Level of Evidence......................................................................................................... 396 21.7 Further Development .................................................................................................. 396 References ...............................................................................................................................
396
T. Kageji, M.D. (*) Department of Neurosurgery, School of Medicine, The University of Tokushima, Kuramoto-cho 3-18-15, Tokushima 770, Japan e-mail: [email protected] Y. Nakagawa, M.D. Department of Neurosurgery, National Kagawa Children’s Hospital, Kagawa, Japan e-mail: [email protected] H. Kumada, M.D. Division of Biomedical, Faculty of Medicine, University of Tsukuba, Tokai, Japan email: [email protected] W.A.G. Sauerwein et al. (eds.), Neutron Capture Therapy, DOI 10.1007/978-3-642-31334-9_21, © Springer-Verlag Berlin Heidelberg 2012
389
390
21.1
T. Kageji et al.
Introduction
The first clinical trials of BNCT were conducted at the Brookhaven Graphic Reactor and the Brookhaven Medical Research Reactor during 1951 and 1952 and at the Massachusetts Institute of Technology Reactor from 1959 to 1962 [3]. The boron compounds used were boric acid and borate as the boron carrier. The clinical results were discouraging: none of the patients survived for 1 year. Serious complications such as acute brain swelling and delayed cerebral necrosis resulted from the high boron content in the blood and normal brain tissue [3]. In 1968, Hatanaka introduced BSH as a boron carrier in Japan, and between 1968 and 1998 more than 170 patients with malignant intracranial tumors, especially GBM, were treated with BNCT in combination with BSH and pure thermal neutron beam [4, 5, 12, 13].
Data Loading...
